Search
Foscarbidopa
go.drugbank.com/drugs/DB16171ApprovedFoscarbidopa is under investigation in clinical trial NCT04379050 (Extension Study to Evaluate Safety and Tolerability of 24-hour Daily Exposure of Continuous Subcutaneous Infusion of ABBV-951 in Adult
Quinupramine
go.drugbank.com/drugs/DB13246ApprovedQuinupramine has been approved in France under the brand name Kinupril, as an antidepressant [A175003].
Gemcabene
go.drugbank.com/drugs/DB05123InvestigationalGemcabene is a new drug that lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C).
Amediplase
go.drugbank.com/drugs/DB06679ExperimentalAmediplase is a recombinant chimeric plasminogen activator, consisting of the kringle 2 domain from the A-chain of tissue plasminogen activator (t-PA) and the carboxy terminal region of pro-urokinase.
Human umbilical cord blood mononuclear cell-conditioned medium
go.drugbank.com/drugs/DB15724ExperimentalThus, the media in which they are cultured is believed to also have therapeutic potential. … Transplantation with human umbilical cord blood mononuclear cells (HUCBC) has demonstrated promising results in various disease states.
LuLym-T
go.drugbank.com/drugs/DB17405ExperimentalLuLym-T is an investigational autologous immune cell therapy consisting of activated T Lymphocytes. Developed by Lukas Biomedical, Inc., it is currently being investigated in hepatocellular carcinoma.
Formebolone
go.drugbank.com/drugs/DB01569IllicitInvestigational[A14416] It is also classified by the US Drug Enforcement Administration as Schedule III drug in the Controlled Substances Act. … Formebolone, a derivative of androstane, is an anabolic androgenic steroid. It is on the list of substances prohibited by the Word Anti-Doping Agency, and is regularly screened for in athletes.
Etidocaine
go.drugbank.com/drugs/DB08987ApprovedEtidocaine is marketed under the name Duranest. It is an injectable local anesthetic during surgery, labor, and delivery.
Arbekacin
go.drugbank.com/drugs/DB06696InvestigationalAn semisynthetic aminoglycoside antibiotic. Often used for treatment of multi-resistant bacterial infection such as methicillin-resistant _Staphylococcus aureus_ (MRSA).
Osanetant
go.drugbank.com/drugs/DB04872InvestigationalIn a review of its R&D portfolio, the company announced in August 2005 that it would cease any further development of osanetant. … Developed by Sanofi-Aventis (formerly Sanofi-Synthelabo), osanetant (SR-142801) is an NK3 receptor antagonist which was under development for the treatment of schizophrenia and other Central Nervous System